一种预测和抑制阿尔茨海默氏症疾病中Amyloid Beta二元化模式的方法
Sreekanya Roy1,2, Sima Biswas1, Anirban Nandy1
1Department of Biochemistry and Biophysics, University of Kalyani, Kalyani, Nadia, West Bengal, India.
Toxicology reports
|January 27, 2025
概括
这项研究使用分子建模来分析阿尔茨海默病 (AD) 粉样蛋白β (Aβ) 二次体,区分野生型与突变型. 它还探讨了重新利用抗炎药物来抑制Aβ二次体的形成,为AD提供了新的治疗途径.
科学领域:
- 神经科学是一个神经科学.
- 计算生物学 计算生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔茨海默病 (AD) 是一种主要的神经退行性疾病.
- 粉样蛋白假设,专注于粉样蛋白β (Aβ) 斑块,是AD病因的一个突出的理论.
- 阿尔茨海默病呈现为零星 (晚期发病) 或家族 (早期发病) 形式,与家族性阿尔茨海默病相关的粉样蛋白前体蛋白 (APP) 突变.
研究的目的:
- 通过分子建模,将零散AD中的野生类型Aβ二元与家族AD中的突变二元区分开来.
- 通过评估它们抑制Aβ二聚体形成的能力,研究重新利用现有的抗炎药物用于AD治疗的潜力.
主要方法:
- 用分子建模分析和区分Aβ二次体.
- 虚拟查和分子对接模拟被用于评估抗炎药物对它们对Aβ二聚体形成的抑制作用.
主要成果:
- 对野生类型和突变Aβ二次体进行了分析,分析了明显的结合相互作用.
- 通过计算分析,几种抗炎药物在抵抗Aβ二次体形成方面表现出强度.
结论:
- 分子建模为AD亚型中的Aβ二次差异提供了洞察力.
- 对抗炎症药物的药物重新定位为阿尔茨海默病的新疗法策略,有可能抑制粉样蛋白斑块的形成.
相关概念视频
Amyloid Fibrils
9.2K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.2K
Alzheimer's Disease: Treatment
160
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
160
Alzheimer's Disease: Overview
439
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
439


